CURRENT STUDIES WITH METHYLGLYOXAL-BIS(GUANYLHYDRAZONE).

摘要: Summary Recently methylglyoxal-bis(guanylhydrazone) elicited considerable interest as an anticancer agent in view of its clinical activity against acute myelocytic leukemia and lymphomatous diseases. The antitumor toxicological effects this compound current pharmacological investigations carried out laboratory are reviewed the present report. delayed hypoglycemia induced by drug rabbits is associated with hepatic necrosis becomes evident only after depletion glycogen. Following administration glucose or galactose, deposition glycogen liver inhibited early 4 hours treatment at a time when not yet histologically evident. possibility discussed that inhibition oxidative phosphorylation may be related to observed. comparative study hypoglycemic several closely analogs revealed minor modifications chemical structure parent greatly diminish potency derivative. In contrast, effect maintained provided structures contain two unsubstituted symmetric guanidine moieties. regression Sarcoma 180 pyridoxine-deficient HaICR Swiss mice allogenic rejection skin grafts exchanged between AKR C57BL/6 antagonized drug. L1210 prevented concurrent spermidine same different route. data available relation possible mechanisms action new agent.